Terms: = Uterine cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
746 results:
1. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
2. Integrated In-Silico and In Vitro analysis to Decipher the contribution of bisphenol-A in cervical cancer.
Khan NG; Adiga D; Rai PS; Kabekkodu SP
Toxicology; 2024 May; 504():153791. PubMed ID: 38555994
[TBL] [Abstract] [Full Text] [Related]
3. Plumbagin as a preferential lead molecule to combat egfr-driven matrix abundance and migration of cervical carcinoma cells.
Krishnamoorthy S; Sabanayagam R; Periyasamy L; Muruganantham B; Muthusami S
Med Oncol; 2024 Mar; 41(4):89. PubMed ID: 38520625
[TBL] [Abstract] [Full Text] [Related]
4. Thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of EGF to inhibit cervical cancer recurrence.
Piao L; Xiang P; Zhou Y; Zhao W; Yang T; Xia S; Gao G; Chen K; Li D
Colloids Surf B Biointerfaces; 2024 Apr; 236():113795. PubMed ID: 38428207
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations.
Klubíčková N; Dermawan JK; Mosaieby E; Martínek P; Vaněček T; Hájková V; Ptáková N; Grossmann P; Šteiner P; Švajdler M; Kinkor Z; Michalová K; Szepe P; Plank L; Hederová S; Kolenová A; Spasov NJ; Kosemehmetoglu K; Pažanin L; Špůrková Z; Baník M; Baumruk L; Meyer A; Kalmykova A; Koshyk O; Michal M; Michal M
J Pathol; 2024 May; 263(1):61-73. PubMed ID: 38332737
[TBL] [Abstract] [Full Text] [Related]
6. The m6A methyltransferase RBM15 affects tumor cell stemness and progression of cervical cancer by regulating the stability of lncRNA HEIH.
Quan Y; Zhou M; Li J; Yang Y; Guo J; Tang T; Liu P
Exp Cell Res; 2024 Mar; 436(2):113924. PubMed ID: 38280435
[TBL] [Abstract] [Full Text] [Related]
7. Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer.
Zhou J; Li H; Wu B; Zhu L; Huang Q; Guo Z; He Q; Wang L; Peng X; Guo T
Sci Rep; 2024 Jan; 14(1):1860. PubMed ID: 38253629
[TBL] [Abstract] [Full Text] [Related]
8. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
9. LncRNA ABHD11-AS1 activates egfr signaling to promote cervical cancer progression by preventing FUS-mediated degradation of ABHD11 mRNA.
Yang T; Tian S; Zhao J; Pei M; Zhao M; Yang X
Cell Cycle; 2023; 22(23-24):2538-2551. PubMed ID: 38146687
[TBL] [Abstract] [Full Text] [Related]
10. Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis.
Vali M; Maleki Z; Nikbakht HA; Hassanipour S; Kouhi A; Nazemi S; Hajizade-Valokolaee M; Nayeb M; Ghaem H
BMC Womens Health; 2023 Dec; 23(1):671. PubMed ID: 38098009
[TBL] [Abstract] [Full Text] [Related]
11. Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report.
Biben E; Menon L; Gokden N; Spond MF; Eichhorn JM; Aydin AM
BMC Urol; 2023 Dec; 23(1):204. PubMed ID: 38066479
[TBL] [Abstract] [Full Text] [Related]
12. Exploration of the Mechanism of Kaempferol in the Treatment of Cervical cancer-based on Metabolomics and Network Pharmacology.
Cao DM; Liu T
Curr Pharm Des; 2023; 29(36):2877-2890. PubMed ID: 38062663
[TBL] [Abstract] [Full Text] [Related]
13. Exploring the utility of FTS as a bonafide binding partner for egfr: A potential drug target for cervical cancer.
Krishnamoorthy S; Muruganantham B; Yu JR; Park WY; Muthusami S
Comput Biol Med; 2023 Dec; 167():107592. PubMed ID: 37976824
[TBL] [Abstract] [Full Text] [Related]
14. A comparative analysis of phyto-components on egfr binding, viability, and migration in HPV positive ME180 and HPV negative C33A cervical cancer cells.
Sabanayagam R; Krishnamoorthy S; Anbuselvam M; Muruganantham B; Muthusami S
Med Oncol; 2023 Nov; 40(12):357. PubMed ID: 37964051
[TBL] [Abstract] [Full Text] [Related]
15. Increased Gene Expression of
Parida P; Lewis S; Sharan K; Kamal MV; Kumar NAN; Godkhindi VM; Varambally S; Rangnekar VM; Rao M; Damerla RR
Cells; 2023 Oct; 12(21):. PubMed ID: 37947608
[No Abstract] [Full Text] [Related]
16. Functional Distinctions of Endometrial cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.
Dixit G; Pappas BA; Bhardwaj G; Schanz W; Maretzky T
Cells; 2023 Sep; 12(18):. PubMed ID: 37759450
[TBL] [Abstract] [Full Text] [Related]
17. Fumarate hydratase functions as a tumor suppressor in endometrial cancer by inactivating egfr signaling.
Wang YY; Vadhan A; Wu CH; Hsu CY; Chen YC; Chen YK; Chen PY; Nguyen HDH; Chang YC; Yuan SF
Oncol Rep; 2023 Oct; 50(4):. PubMed ID: 37615251
[TBL] [Abstract] [Full Text] [Related]
18. EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells.
Sabanayagam R; Krishnamoorthy S; Gnanagurusamy J; Muruganatham B; Muthusami S
Med Oncol; 2023 Aug; 40(9):261. PubMed ID: 37544940
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of egfr inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Krishna A; Sathya M; Mukesh S; Athiyamaan MS; Banerjee S; Sunny J; Srinivas C; Lobo D; Makkapatti BS; Jawahar V
Med Oncol; 2023 Jun; 40(7):203. PubMed ID: 37310466
[TBL] [Abstract] [Full Text] [Related]
[Next]
